19-12807328-C-T
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 7P and 0B. PM2PP3_StrongPP5
The NM_006397.3(RNASEH2A):c.322C>T(p.Arg108Trp) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R108G) has been classified as Uncertain significance.
Frequency
Consequence
NM_006397.3 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes  
GnomAD2 exomes  AF:  0.00  AC: 0AN: 251478 AF XY:  0.00   
GnomAD4 exome Cov.: 32 
GnomAD4 genome  
ClinVar
Submissions by phenotype
Aicardi-Goutieres syndrome 4    Pathogenic:2Uncertain:1Other:1 
- -
- -
The missense variant p.R108W in RNASEH2A (NM_006397.3) has ben previously reported in affected patients (Stephanie R Coffin et al). Functional studies have not been performed. It has been submitted to ClinVar as Pathogenic. It is novel (not in any individuals) in gnomAD ExomesThe p.R108W variant is novel (not in any individuals) in 1000 Genomes. In silico tools predict the variant to be damaging and the residue is moderately conserved across species. For these reasons, this variant has been classified as Likely Pathogenic. -
ClinVar contains an entry for this variant (Variation ID: 126397). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on RNASEH2A function (PMID: 21454563). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This missense change has been observed in individual(s) with Aicardi-Goutieres syndrome (PMID: 31130681). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 108 of the RNASEH2A protein (p.Arg108Trp). -
Aicardi Goutieres syndrome    Pathogenic:1 
Variant summary: RNASEH2A c.322C>T (p.Arg108Trp) results in a non-conservative amino acid change located in the Ribonuclease HII/HIII domain (IPR024567) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. In addition, the variant affects the penultimate nucleotide of exon 3, therefore might also affect splicing. Several computational tools predict a significant impact on normal splicing: one predict the variant no significant impact on splicing, two predict the variant weakens a 5' donor site, while one predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 251478 chromosomes (gnomAD v2.1). The variant c.322C>T has been reported in the literature in compound heterozygous- and homozygous individuals affected with Aicardi Goutieres Syndrome (e.g. Rice_2007, Rice_2013, Garau_2019, Ganapathy_2019, Wang_2022). These data indicate that the variant is likely to be associated with disease. Publications also reported experimental evidence evaluating an impact on protein function and demonstrated moderately decreased catalytic efficiency and nucleic acid binding (Coffin_2011), however, since authors used bacterially expressed (intronless) cDNA constructs (which don't undergo splicing) therefore the activities in these assays might not reflect the overall in vivo consequences of this variant. In addition, mitochondrial dysfunction was reported in lymphoblastoid cell lines (LCLs), derived from a compound heterozygous patient (Dragoni_2022). The following publications have been ascertained in the context of this evaluation (PMID: 17846997, 24183309, 33707687, 31069529, 35551623, 21454563, 36430958). ClinVar contains an entry for this variant (Variation ID: 126397). Based on the evidence outlined above, the variant was classified as likely pathogenic. -
not provided    Pathogenic:1 
Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies suggest a damaging effect on catalytic efficiency and binding affinity (PMID: 21454563); In silico analyses support that this missense variant has a deleterious effect on protein structure/function and a deleterious effect on splicing; This variant is associated with the following publications: (PMID: 36430958, 31069529, 31130681, 17846997, 35551623, 33707687, 21454563) -
Computational scores
Source: 
Splicing
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at